Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Tempest Therapeutics, Inc. is a clinical-stage biotech company developing targeted and immune-mediated cancer therapies. Its pipeline includes first-in-class oral small molecules like amezalpat for hepatocellular carcinoma and TPST-1495 targeting prostaglandin receptors. The company focuses on innovative oncology treatments, leveraging scientific research, strategic collaborations, and patent protection to address unmet medical needs in cancer markets worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.